Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline Review, H2 2016’, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

The report reviews pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) therapeutics and enlists all their major and minor projects

The report assesses Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

Actinium Pharmaceuticals, Inc.

ADC Therapeutics SA

Affimed GmbH

Altor BioScience Corporation

Amgen Inc.

ARA Healthcare Pvt. Ltd.

Ariad Pharmaceuticals, Inc.

Array BioPharma Inc.

Atara Biotherapeutics, Inc.

Bellicum Pharmaceuticals, Inc.

Bexion Pharmaceuticals, LLC

Bio-Path Holdings, Inc.

BioSight Ltd.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Cantargia AB

Celgene Corporation

Cellectar Biosciences, Inc.

Cellectis S.A.

Cellular Biomedicine Group, Inc.

Ceronco Biosciences

Cielo Therapeutics Inc

Constellation Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc.

Daiichi Sankyo Company, Limited

DiNonA Inc.

Eli Lilly and Company

EpiZyme, Inc.

Erytech Pharma SA

Eureka Therapeutics, Inc.

Fate Therapeutics, Inc.

Formula Pharmaceuticals, Inc.

Gamida Cell Ltd.

GlaxoSmithKline Plc

Hangzhou Minsheng Pharmaceutical Group Co.,Ltd

iDD biotech SAS

Immunomedics, Inc.

Incyte Corporation

Intech Biopharm Ltd

Interprotein Corporation

Jasco Pharmaceuticals, LLC.

Jazz Pharmaceuticals Plc

Johnson & Johnson

Juno Therapeutics Inc.

Karyopharm Therapeutics, Inc.

Kiadis Pharma N.V.

Kite Pharma Inc

Les Laboratoires Servier SAS

medac GmbH

Merck & Co., Inc.

Mesoblast Limited

Millennium Pharmaceuticals Inc

Moleculin Biotech Inc

Nanovalent Pharmaceuticals Inc.

Novartis AG

NovImmune SA

NuCana BioMed Limited

Omeros Corporation

OncoTartis, Inc.

OncoTherapy Science, Inc.

Oncternal Therapeutics, Inc.

Oribase Pharma

OSE Immunotherapeutics

Pfenex Inc.

Pfizer Inc.

Pharma Mar, S.A.

Portola Pharmaceuticals, Inc.

Red5 Pharmaceuticals, LLC

Regeneron Pharmaceuticals Inc

Sanofi

Sareum Holdings Plc

Seattle Genetics, Inc.

Sellas Inc

Shire Plc

Spectrum Pharmaceuticals, Inc.

Stemline Therapeutics, Inc.

SYNIMMUNE GmbH

Syros Pharmaceuticals Inc

Takeda Pharmaceutical Company Limited

TetraLogic Pharmaceuticals

Theravectys SA

Threshold Pharmaceuticals, Inc.

Tolero Pharmaceuticals, Inc.

Tragara Pharmaceuticals, Inc.

Verastem, Inc.

VioQuest Pharmaceuticals, Inc.

Xbrane Biopharma AB

ZIOPHARM Oncology, Inc.

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview 8

Therapeutics Development 9

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies 11

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes 18

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance 20

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies 23

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes 34

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development 36

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment 126

Drug Profiles 148

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects 642

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products 649

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones 651

Appendix 659

List of Tables

List of Tables

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2016 29

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Comparative Analysis, H2 2016 30

Number of Products under Development by Companies, H2 2016 31

Number of Products under Development by Companies, H2 2016 (Contd..1) 32

Number of Products under Development by Companies, H2 2016 (Contd..2) 33

Number of Products under Development by Companies, H2 2016 (Contd..3) 34

Number of Products under Development by Companies, H2 2016 (Contd..4) 35

Number of Products under Development by Companies, H2 2016 (Contd..5) 36

Number of Products under Development by Companies, H2 2016 (Contd..6) 37

Number of Products under Investigation by Universities/Institutes, H2 2016 39

Comparative Analysis by Late Stage Development, H2 2016 40

Comparative Analysis by Clinical Stage Development, H2 2016 41

Comparative Analysis by Early Stage Development, H2 2016 42

Products under Development by Companies, H2 2016 43

Products under Development by Companies, H2 2016 (Contd..1) 44

Products under Development by Companies, H2 2016 (Contd..2) 45

Products under Development by Companies, H2 2016 (Contd..3) 46

Products under Development by Companies, H2 2016 (Contd..4) 47

Products under Development by Companies, H2 2016 (Contd..5) 48

Products under Development by Companies, H2 2016 (Contd..6) 49

Products under Development by Companies, H2 2016 (Contd..7) 50

Products under Development by Companies, H2 2016 (Contd..8) 51

Products under Development by Companies, H2 2016 (Contd..9) 52

Products under Development by Companies, H2 2016 (Contd..10) 53

Products under Investigation by Universities/Institutes, H2 2016 54

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 55

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by 4SC AG, H2 2016 56

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Actinium Pharmaceuticals, Inc., H2 2016 57

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by ADC Therapeutics SA, H2 2016 58

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Affimed GmbH , H2 2016 59

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Altor BioScience Corporation, H2 2016 60

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Amgen Inc., H2 2016 61

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by ARA Healthcare Pvt. Ltd., H2 2016 62

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Ariad Pharmaceuticals, Inc., H2 2016 63

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Array BioPharma Inc., H2 2016 64

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Atara Biotherapeutics, Inc., H2 2016 65

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 66

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bexion Pharmaceuticals, LLC, H2 2016 67

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bio-Path Holdings, Inc., H2 2016 68

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by BioSight Ltd., H2 2016 69

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Boehringer Ingelheim GmbH, H2 2016 70

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bristol-Myers Squibb Company, H2 2016 71

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Calithera Biosciences, Inc., H2 2016 72

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cantargia AB, H2 2016 73

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Celgene Corporation, H2 2016 74

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cellectar Biosciences, Inc., H2 2016 75

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cellectis S.A., H2 2016 76

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cellular Biomedicine Group, Inc., H2 2016 77

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Ceronco Biosciences, H2 2016 78

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cielo Therapeutics Inc, H2 2016 79

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Constellation Pharmaceuticals, Inc., H2 2016 80

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016 81

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 82

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by DiNonA Inc., H2 2016 83

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Eli Lilly and Company, H2 2016 84

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by EpiZyme, Inc., H2 2016 85

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Erytech Pharma SA, H2 2016 86

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Eureka Therapeutics, Inc., H2 2016 87

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Fate Therapeutics, Inc., H2 2016 88

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Formula Pharmaceuticals, Inc., H2 2016 89

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Gamida Cell Ltd., H2 2016 90

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by GlaxoSmithKline Plc, H2 2016 91

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Hangzhou Minsheng Pharmaceutical Group Co.,Ltd, H2 2016 92

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by iDD biotech SAS, H2 2016 93

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Immunomedics, Inc., H2 2016 94

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Incyte Corporation, H2 2016 95

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Intech Biopharm Ltd, H2 2016 96

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Interprotein Corporation, H2 2016 97

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Jasco Pharmaceuticals, LLC., H2 2016 98

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Jazz Pharmaceuticals Plc, H2 2016 99

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Johnson & Johnson, H2 2016 100

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Juno Therapeutics Inc., H2 2016 101

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 102

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Kiadis Pharma N.V., H2 2016 103

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Kite Pharma Inc, H2 2016 104

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Les Laboratoires Servier SAS, H2 2016 105

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by medac GmbH, H2 2016 106

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Merck & Co., Inc., H2 2016 107

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Mesoblast Limited, H2 2016 108

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 109

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Moleculin Biotech Inc, H2 2016 110

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Nanovalent Pharmaceuticals Inc., H2 2016 111

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Novartis AG, H2 2016 112

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by NovImmune SA, H2 2016 113

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by NuCana BioMed Limited, H2 2016 114

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Omeros Corporation, H2 2016 115

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by OncoTartis, Inc., H2 2016 116

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by OncoTherapy Science, Inc., H2 2016 117

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Oncternal Therapeutics, Inc., H2 2016 118

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Oribase Pharma, H2 2016 119

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by OSE Immunotherapeutics, H2 2016 120

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Pfenex Inc., H2 2016 121

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Pfizer Inc., H2 2016 122

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Pharma Mar, S.A., H2 2016 123

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Portola Pharmaceuticals, Inc., H2 2016 124

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Red5 Pharmaceuticals, LLC, H2 2016 125

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 126

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Sanofi, H2 2016 127

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Sareum Holdings Plc, H2 2016 128

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Seattle Genetics, Inc., H2 2016 129

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Sellas Inc, H2 2016 130

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Shire Plc, H2 2016 131

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 132

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Stemline Therapeutics, Inc., H2 2016 133

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by SYNIMMUNE GmbH, H2 2016 134

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Syros Pharmaceuticals Inc, H2 2016 135

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 136

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by TetraLogic Pharmaceuticals, H2 2016 137

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Theravectys SA, H2 2016 138

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Threshold Pharmaceuticals, Inc., H2 2016 139

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Tolero Pharmaceuticals, Inc., H2 2016 140

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Tragara Pharmaceuticals, Inc., H2 2016 141

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Verastem, Inc., H2 2016 142

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by VioQuest Pharmaceuticals, Inc., H2 2016 143

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Xbrane Biopharma AB, H2 2016 144

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by ZIOPHARM Oncology, Inc., H2 2016 145

Assessment by Monotherapy Products, H2 2016 146

Assessment by Combination Products, H2 2016 147

Number of Products by Stage and Target, H2 2016 149

Number of Products by Stage and Mechanism of Action, H2 2016 157

Number of Products by Stage and Route of Administration, H2 2016 165

Number of Products by Stage and Molecule Type, H2 2016 167

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects, H2 2016 662

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects (Contd..1), H2 2016 663

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects (Contd..2), H2 2016 664

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects (Contd..3), H2 2016 665

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects (Contd..4), H2 2016 666

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects (Contd..5), H2 2016 667

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects (Contd..6), H2 2016 668

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Discontinued Products, H2 2016 669

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Discontinued Products (Contd..1), H2 2016 670

List of Figures

List of Figures

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2016 29

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Comparative Analysis, H2 2016 30

Number of Products under Development by Companies, H2 2016 31

Number of Products under Investigation by Universities/Institutes, H2 2016 38

Comparative Analysis by Late Stage Development, H2 2016 40

Comparative Analysis by Clinical Stage Development, H2 2016 41

Comparative Analysis by Early Stage Products, H2 2016 42

Assessment by Monotherapy Products, H2 2016 146

Assessment by Combination Products, H2 2016 147

Number of Products by Top 10 Targets, H2 2016 148

Number of Products by Stage and Top 10 Targets, H2 2016 148

Number of Products by Top 10 Mechanism of Actions, H2 2016 156

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 156

Number of Products by Routes of Administration, H2 2016 164

Number of Products by Stage and Routes of Administration, H2 2016 164

Number of Products by Top 10 Molecule Types, H2 2016 166

Number of Products by Stage and Top 10 Molecule Types, H2 2016 166

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared